Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ASCO 2022 > Miscellaneous Topics > Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma 

Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma 

Presented by
Prof. Eric Bouffet, University of Toronto, Canada
Conference
ASCO 2022
Doi
https://doi.org/10.55788/a2dfdc9e

    The non-chemotherapeutic combination of dabrafenib and trametinib outperformed standard-of-care chemotherapy in paediatric patients with BRAF V600-mutated low-grade glioma. With the manageable safety profile, it shows potential as a new standard-of-care for this population. 

    Gliomas, accounting for approximately 45% of all paediatric central nervous system tumours, are surgically treated if possible [1]. Unfortunately, about 50% of these tumours cannot be resected, because the tumours are too large or inaccessible. Chemotherapy is the first-line standard of care in these patients. However, paediatric patients with BRAF V600E mutations show a less favourable response to chemotherapy and novel therapeutic options are needed for these patients [2]. Prof. Eric Bouffet (University of Toronto, Canada) presented results from a phase 2 trial (NCT02684058) which randomised patients with BRAF V600-mutant low-grade glioma to dabrafenib plus trametinib (n=73) or chemotherapy (carboplatin plus vincristine; n=37) [3]. Objective response rate (ORR) per central independent review was the primary endpoint.

    The experimental arm showed superior ORR compared with the chemotherapy arm (47% vs 11%; OR 7.2; P<0.001). Most objective responses were partial responses in the experimental arm (44%) and in the chemotherapy arm (8%). The differences between the treatment arms were the most pronounced in ganglioglioma (ORR 38% vs 0%), low-grade glioma not otherwise specified (ORR 86% vs 17%), pilocytic astrocytoma (ORR 41% vs 8%), and pleomorphic xanthoastrocytoma (ORR 33% vs 0%). Furthermore, the progression-free survival (PFS) after 12 months favoured the experimental arm over the placebo arm (66.6% vs 26.1%; HR 0.31; P<0.001). These results were also reflected in the reported quality-of-life scores, which were improved in the experimental arm compared with the chemotherapy arm.

    The safety analysis displayed that grade ≥3 adverse events (AEs) were more common in the chemotherapy arm (94% vs 47%). Similarly, treatment-related discontinuation rates were higher in the chemotherapy arm (9% vs 3%). Pyrexia (68%), headache (47%), and dry skin (26%) were more frequently reported in the experimental arm, whereas vomiting, nausea, and marrow-related issues were more common in the chemotherapy arm.

    “In paediatric patients with BRAF V600-mutant low-grade glioma, the combination of dabrafenib plus trametinib was superior to standard-of-care frontline chemotherapy, with a manageable safety profile, demonstrating potential as a new standard-of-care for this population,” concluded Prof. Bouffet.

    1. Ostrom QT, et al. Neuro Oncol. 2021;23:301‒305.
    2. Lassaletta A, et al. J Clin Oncol. 2017;35(25):2934‒2941.
    3. Bouffet E, et al. Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600–mutant pediatric low-grade glioma (pLGG). LBA2002, ASCO 2022 Annual Meeting, 3–7 June, Chicago, IL, USA.

    Copyright ©2022 Medicom Medical Publishers



    Posted on